What is it about?
Crossover trial: melatonin impairs glucose tolerance in the common MTNR1B T2D risk carriers by reducing first-phase β-cell response & insulin feedback—supporting genotype-tailored melatonin timing.
Featured Image
Read the Original
This page is a summary of: Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With
MTNR1B
Diabetes Risk Variant, Diabetes Care, June 2026, American Diabetes Association,
DOI: 10.2337/dc26-0164.
You can read the full text:
Contributors
The following have contributed to this page
